News
AKTS
19.33
-2.03%
-0.40
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and Multiple High-Value Oncology Targets
TipRanks · 1d ago
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS)
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)
TipRanks · 1d ago
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
TipRanks · 1d ago
Aktis Oncology, Inc. reports Q1 results
Seeking Alpha · 1d ago
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Reuters · 1d ago
Aktis Oncology Q1 FY26 net loss widens to $18.3 million; revenue climbs to $3.2 million
PUBT · 1d ago
*Aktis Oncology 1Q Rev $3.23M >AKTS
Dow Jones · 1d ago
AKTIS ONCOLOGY REPORTS FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
Reuters · 1d ago
*Aktis Oncology 1Q Loss $18.3M >AKTS
Dow Jones · 1d ago
Press Release: Aktis Oncology Reports Financial -2-
Dow Jones · 1d ago
Press Release: Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Dow Jones · 1d ago
Weekly Report: what happened at AKTS last week (0504-0508)?
Weekly Report · 2d ago
Aktis Oncology CEO presents at BofA Securities Health Care Conference webcast
PUBT · 05/06 12:08
Aktis Oncology Initiated at Buy on Differentiated Radiopharmaceutical Platform and mCRPC Opportunity for AKY‑2519
TipRanks · 05/05 15:45
Aktis Oncology posts presentation outlining AKY-2519 Phase 1b clinical development strategy
PUBT · 05/05 12:08
Aktis Oncology initiates clinical trial of AKY-25191
TipRanks · 05/04 21:11
Aktis Oncology Starts Phase 1b Clinical Study Of AKY-25191 In Participants With Metastatic Castration-resistant Prostate Cancer
Benzinga · 05/04 20:28
AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL FOR AKY-2519, A B7-H3 MINIPROTEIN RADIOCONJUGATE, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Reuters · 05/04 20:05
Weekly Report: what happened at AKTS last week (0427-0501)?
Weekly Report · 05/04 10:42
More
Webull provides a variety of real-time AKTS stock news. You can receive the latest news about AKTIS ONCOLOGY INC through multiple platforms. This information may help you make smarter investment decisions.
About AKTS
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.